DUSA PHARMACEUTICALS, INC.
NASDAQ : DUSA

DUSA PHARMACEUTICALS, INC.

February 01, 2006 06:30 ET

DUSA Pharmaceuticals, Inc. to Host Fourth Quarter and Full Year 2005 Financial Results and Corporate Highlights Conference Call

WILMINGTON, MASSACHUSETTS--(CCNMatthews - Feb. 1, 2006) - DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA) announces that its corporate highlights and year end financial results press release will be issued on Monday, February 6th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.



Monday, February 6, 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.936.4602
Password - DUSA

For International callers use
507.726.3418
Password - DUSA

A recorded replay of the call will be available by 12:00 pm
North American callers 800.334.2128
International callers 620.294.2986


The call will be accessible on our web site after 1:00 p.m. www.dusapharma.com.

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development and marketing of Levulan Photodynamic Therapy (PDT) and Photodetection (PD) for multiple medical conditions, with a primary focus on dermatology. PDT and PD utilize light-activated compounds to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. DUSA maintains offices in Wilmington, MA, Valhalla, NY and Toronto, Ontario. DUSA has also announced the signing of a definitive merger agreement with Sirius Laboratories of Vernon Hills, IL.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    (416) 363-6602 (FAX)
    www.dusapharma.com